Physician profile
Charu K Jain
NPI 1720214349
$673.64
in general payments reported to CMS, 2019-2025
13 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.44 · 2021: $35.19 · 2022: $18.07 · 2023: $61.93 · 2024: $117 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $242.26 | 2024-2025 | |
| Exeltis, USA INC. | $166.06 | 2023-2025 | Slynd |
| Daiichi Sankyo INC. | $45.54 | 2023-2024 | Injectafer |
| Abbvie INC. | $42.62 | 2021-2023 | |
| Astellas Pharma US INC | $29.85 | 2019 | |
| Sage Therapeutics, LLC | $25.83 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $24.98 | 2025 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $18.34 | 2024 | Paragard T 380a |
| Agile Therapeutics, INC. | $18.07 | 2022 | |
| Amgen INC. | $17.65 | 2019 | |
| Organon LLC | $16.26 | 2025 | |
| Merck Sharp & Dohme LLC | $13.94 | 2019 | |
| Pfizer INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charu Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.